A detailed history of Royal Bank Of Canada transactions in Opti Nose, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 100 shares of OPTN stock, worth $42. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 138 27.54%
Holding current value
$42
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.67 - $1.27 $25 - $48
-38 Reduced 27.54%
100 $0
Q2 2024

Aug 14, 2024

SELL
$0.82 - $1.44 $3,794 - $6,664
-4,628 Reduced 97.1%
138 $0
Q1 2024

Nov 05, 2024

BUY
$1.17 - $1.94 $5,414 - $8,978
4,628 Added 3353.62%
4,766 $6,000
Q1 2024

May 15, 2024

SELL
$1.17 - $1.94 $21,426 - $35,527
-18,313 Reduced 79.35%
4,766 $6,000
Q4 2023

Feb 14, 2024

BUY
$1.02 - $1.47 $13,563 - $19,548
13,298 Added 135.96%
23,079 $29,000
Q3 2023

Nov 14, 2023

BUY
$0.93 - $1.38 $569 - $844
612 Added 6.67%
9,781 $12,000
Q2 2023

Aug 14, 2023

BUY
$1.11 - $2.05 $8,906 - $16,449
8,024 Added 700.79%
9,169 $11,000
Q1 2023

May 15, 2023

BUY
$1.63 - $2.02 $1,703 - $2,110
1,045 Added 1045.0%
1,145 $2,000
Q4 2022

Feb 14, 2023

SELL
$1.68 - $3.7 $144 - $318
-86 Reduced 46.24%
100 $0
Q3 2022

Nov 14, 2022

BUY
$3.43 - $4.01 $294 - $344
86 Added 86.0%
186 $0
Q4 2021

Feb 14, 2022

SELL
$1.55 - $3.1 $13,407 - $26,815
-8,650 Reduced 98.86%
100 $0
Q3 2021

Nov 15, 2021

SELL
$2.35 - $3.16 $10,725 - $14,422
-4,564 Reduced 34.28%
8,750 $26,000
Q2 2021

Aug 16, 2021

BUY
$2.91 - $3.83 $38,743 - $50,992
13,314 New
13,314 $41,000

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $35M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.